Pediatric Osteosarcoma Update
Osteosarcoma, the most common type of primary malignant bone tumor, is defined by the presence of malignant mesenchymal cells producing osteoid or immature bone. During this lecture, Dr. Meyers will explain the evolving role of genomic profiling in diagnosing and treating pediatric osteosarcoma, as well as, reviewing the use of histologic necrosis following initial chemotherapy in the treatment of pediatric osteosarcoma.
Pediatricians, Pediatric Oncologists, Hematologists/Oncologists, Infectious Disease Pediatricians, Pediatric General Internists, Family Physicians, Neonatologists, ED Physicians, Pharmacists and all other interested healthcare providers who care for children with cancer.
- Summarize the meaning and use of histologic necrosis following initial chemotherapy in the treatment of osteosarcoma.
- Describe the evolving role of genomic profiling in the diagnosis and treatment of osteosarcoma.
Paul A. Meyers, M.D.
Chief of Sarcoma Service
Vice Chair for Clinical Affairs
Memorial Sloan Kettering Cancer Center
New York, New York
Paul A. Meyers, M.D., faculty for this educational activity, has indicated that he is a consultant with Boehringer Ingelheim, Genentech and Eli Lilly and is on the speakers' bureau with Genentech. He is a shareholder with Amgen. He will include off-label or unapproved product usage in his presentation or discussion.
All of the relevant financial relationships listed for this individual has been mitigated.
This online course is a highlight from the Kids with Cancer Symposium.
Doured Daghistani, M.D.
Baptist, Homestead and South Miami Hospitals
Ziad Khatib, M.D.
Director of Medical Neuro-Oncology
Division of Pediatric Hematology/Oncology
Clinical Associate Professor
Department of Pediatrics
Florida International University
Kidz Medical Services
Nicklaus Children’s Hospital
Doured Dahgistani, M.D., and Ziad Khatib, M.D., symposium directors, have no relevant financial relationship with ineligible companies* to disclose.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.
*Ineligible companies -- Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 AMA PRA Category 1 Credit™
- 0.50 General certificate of attendance
- 0.50 Florida Board of Pharmacy
This site is supported on the most recent stable releases of the following browsers:
This site is supported on the following mobile devices:
If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.